0001140361-24-011633.txt : 20240306 0001140361-24-011633.hdr.sgml : 20240306 20240306120205 ACCESSION NUMBER: 0001140361-24-011633 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240305 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240306 DATE AS OF CHANGE: 20240306 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nuwellis, Inc. CENTRAL INDEX KEY: 0001506492 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 680533453 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35312 FILM NUMBER: 24724901 BUSINESS ADDRESS: STREET 1: 12988 VALLEY VIEW ROAD CITY: EDEN PRAIRIE STATE: MN ZIP: 55344 BUSINESS PHONE: 952-345-4200 MAIL ADDRESS: STREET 1: 12988 VALLEY VIEW ROAD CITY: EDEN PRAIRIE STATE: MN ZIP: 55344 FORMER COMPANY: FORMER CONFORMED NAME: CHF Solutions, Inc. DATE OF NAME CHANGE: 20170523 FORMER COMPANY: FORMER CONFORMED NAME: Sunshine Heart, Inc. DATE OF NAME CHANGE: 20101124 8-K 1 ef20023378_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  March 5, 2024
 
Nuwellis, Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware
001-35312
No. 68-0533453
(State or Other Jurisdiction of Incorporation or Organization)
(Commission File Number)
(I.R.S. Employer
Identification No.)

12988 Valley View Road, Eden Prairie, MN 55344
(Address of Principal Executive Offices) (Zip Code)

(952) 345-4200
(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NUWE
Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02
Results of Operations and Financial Condition.

On March 5, 2024, Nuwellis, Inc. (the “Company”) issued a press release reporting its financial results for the twelve months ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information included in this Item on Current Report on Form 8-K (including Exhibit 99.1) is furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Item 9.01
Financial Statements and Exhibits

(d)
Exhibits

Exhibit
No.
Description
   
Press Release, dated March 5, 2024, reporting the financial results of Nuwellis, Inc. for the twelve months ended December 31, 2023.
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: March 6, 2024
NUWELLIS, INC.
     
 
By:
/s/ NESTOR JARAMILLO, JR.
 
 
Name:
Nestor Jaramillo, Jr.
 
Title:
Chief Executive Officer



 
EX-99.1 2 ef20023378_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1





Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
Strengthens Its Foundation for Growth, Strong Pediatric Sales, Expanding Margins and Increases Number of New Hospital Accounts

Minneapolis, MN, March 5, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Highlights:

Record quarter revenue of $2.6 million, a 9% increase over prior-year period. Full year revenue of $8.9 million, a 4% increase over 2022.
Fourth quarter pediatric revenue grew 35% year over year; 28% increase in utilization and a 49% increase in console sales. Four new pediatric accounts.
Fourth quarter gross margin of 54.4%. Full year 2023 gross margin of 56.2%, a 56-basis point increase over full year 2022.
Added two products: The new 12 cm dELC catheter and the Quelimmune™ SCD pediatric device.
New clinical case series expands the use of Aquadex® into end-stage liver disease.
New real-world clinical data continues to show Aquadex clinical evidence benefits pediatric patients.
Nuwellis hosted a symposium on March 4 at the Technology and Heart Failure Therapeutics (THT) conference, where two late breaking clinical trials and one lecture session will be presented on the Aquadex system.

“Nuwellis continues to execute on its strategic growth initiatives, with the highest total quarter of organic revenue in company history,” said Nestor Jaramillo, President and CEO of Nuwellis. “Led by Pediatrics, which saw steady increases in existing console utilization and new account openings expanded Aquadex market penetration. We expect our accelerating momentum to continue in 2024, with further support from our growing body of clinical evidence, paving the way for new Aquadex applications such as in end-stage liver disease, as well as new product introductions.

Nuwellis announced the FDA HDE approval for Quelimmune, received by its exclusive U.S. license and distribution partner, SeaStar, further bolstering its pediatric portfolio for Nuwellis’ fast-growing customer category and foundation for growth. Additionally, the introduction of Nuwellis’ recently FDA cleared specialty dual lumen 12 cm catheter will provide clinicians with an additional venous access option to use the company’s Aquadex ultrafiltration system. The company also announced a new clinical case series featured in Clinical Transplantation demonstrating the use of Aquadex to safely and effectively remove fluid volume for end-stage liver disease patients, representing an additional clinical application for Aquadex already within its current FDA labeling. In this case series, Aquadex was shown to reduce cirrhosis-related frailty and enhanced patients’ ability to receive a life-saving liver transplant. Finally, the company announced new real-world data featured in Pediatric Nephrology that showed the proprietary hematocrit sensor within the Aquadex system facilitated guided therapy of fluid overloaded pediatric patients without hemodynamic instability or other complications.

“We overcame challenges like hospital budgetary constraints and nursing shortages in the first half of 2023, achieving 27% revenue growth in the second half of 2023 versus the first half of 2023,” added Mr. Jaramillo. “We've confidently transitioned beyond prior headwinds and anticipate a strong revenue year in 2024, marked by achieving key milestones including the three podium presentations at the THT conference, one of which establishes the clinical superiority of Aquadex over diuretics, new products for our existing pediatric customers, completion of the DaVita Pilot phase, and the IDE submission for our pediatric dedicated renal disease device branded Vivian. We are balancing the multiple growth catalysts mentioned above with the need to raise capital this year. We have recently undertaken steps to reduce our monthly cash burn rate by approximately 40%, balanced against our strategic growth initiatives, which will provide more flexibility in anticipation of tougher capital market conditions for microcap companies like Nuwellis.”


Fourth Quarter 2023 Financial Results

Revenue for the fourth quarter of 2023 was $2.6 million, a 9% increase compared to $2.3 million in the prior-year period. The year over year increase is attributable to an increase in disposable utilization and record international sales.

Gross margin was 54.4% for the fourth quarter of 2023, compared to 56.9% in the prior-year period, a decrease of 250 basis points. The decline was due to product and geographical sales mix and lower fixed overhead manufacturing absorption, leading to more efficient inventory levels.

Selling, general and administrative expenses for the fourth quarter of 2023 were $3.6 million, compared to $4.7 million in the prior-year period. The decrease in SG&A expenses was primarily due to reduced headcount and related compensation expense.

Fourth quarter research and development expenses were $1.4 million, compared to $1.2 million in the prior-year period, reflecting a modest increase in R&D spend related to the development of our new pediatric dedicated CRRT device as we approach IDE submission.

In the current year period, the company recorded a non-recurring expense reduction of approximately $800 thousand, reducing incentive compensation, impacting both SG&A and R&D.  Additionally, the company recorded a $550 thousand SG&A expense, in the current year period, for contractual spend related to the SeaStar license and distribution agreement.

Total operating expenses for the fourth quarter of 2023 were $5.0 million, a 15% decrease compared to $5.9 million in the prior-year period. The $884 thousand decrease was due to cost saving measures implemented early in the second half of the year and carried through year-end 2023 as we continue to drive operating efficiencies.

Operating loss for the fourth quarter of 2023 was $3.6 million compared to an operating loss of $4.5 million in the prior year period, resulting in a $941 thousand period over period reduction.

Net loss attributable to common shareholders for the fourth quarter of 2023 was $7.9 million, or a loss of $2.24 per basic and diluted common share, compared to a net loss attributable to common shareholders of $1.9 million, or a loss of $5.00 per basic and diluted common share in the prior-year period. The current period net loss attributable to common shareholders includes $2.0 million of ‘Other Expense’ and $2.4 million of a deemed dividend and PIK dividend related to the Company’s October 2023 financing. The prior year period net loss attributable to common shareholders includes $2.6 million of ‘Other Income’ related to the Company’s October 2022 financing.

At December 31, 2023, the Company had no debt, cash and cash equivalents of approximately $3.8 million, and approximately 5.7 million common shares outstanding.


Webcast and Conference Call Information
 
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance.

To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-833-816-1404 (U.S) or 1-412-317-0497 (international) and using the conference ID: 10185035. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit ir.nuwellis.com or visit us on LinkedIn or X.

About the Aquadex SmartFlow® System 
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2024 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

CONTACTS

INVESTORS:
Vivian Cervantes
Gilmartin Group
ir@nuwellis.com

NUWELLIS, INC. AND SUBSIDIARY
Consolidated Balance Sheets
(in thousands, except share and per share amounts)

   
December 31,
2023
   
December 31, 2022
 
ASSETS
 
(unaudited)
       
Current assets
           
        Cash and cash equivalents
 
$
3,800
   
$
17,737
 
Marketable securities
   
     
569
 
        Accounts receivable
   
1,951
     
1,406
 
        Inventories, net
   
1,997
     
2,661
 
        Other current assets
   
461
     
396
 
Total current assets
   
8,209
     
22,769
 
        Property, plant and equipment, net
   
728
     
980
 
        Operating lease right-of-use asset
   
713
     
903
 
        Other assets
   
120
     
21
 
TOTAL ASSETS
 
$
9,770
   
$
24,673
 
                 
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
               
Current liabilities
               
          Accounts payable and accrued liabilities
 
$
2,380
   
$
2,245
 
          Accrued compensation
   
525
     
2,161
 
          Current portion of operating lease liability
   
216
     
196
 
          Current portion of finance lease liability
   
     
28
 
          Other current liabilities
   
51
     
58
 
Total current liabilities
   
3,172
     
4,688
 
Common stock warrant liability
   
2,843
     
6,868
 
          Operating lease liability
   
544
     
760
 
Total liabilities
   
6,559
     
12,316
 
Commitments and contingencies
               
                 
Mezzanine Equity
   

     
 
Series J Convertible Preferred Stock as of December 31, 2023 and December 31, 2022, par value $0.0001 per share; authorized 600,000 and none, issued and outstanding 11,950 and none, respectively
   
221
     
 
                 
Stockholders’ equity
               
Series A junior participating preferred stock as of December 31, 2023 and December 31, 2022, par value $0.0001 per share; authorized 30,000 shares, none outstanding
   
     
 
Series F convertible preferred stock as of December 31, 2023 and December 31, 2022, par value $0.0001 per share; authorized 18,000 shares, issued and outstanding 127 shares
   
     
 
Series I convertible preferred stock as of December 31, 2023 and December 31, 2022, par value $0.0001 per share; authorized 1,049,280, issued and outstanding none and 1,049,280, respectively
   
     
 
Preferred stock as of December 31, 2023 and December 31, 2022, par value $0.0001 per share; authorized 39,802,000 shares, none outstanding
   
     
 
Common stock as of December 31, 2023 and December 31, 2022, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 5,682,461 and 536,394, respectively
   
1
     
 
Additional paid‑in capital
   
290,646
     
279,736
 
Accumulated other comprehensive income:
               
     Foreign currency translation adjustment
   
(31
)
   
(18
)
Unrealized gain on marketable securities
   
     
56
 
Accumulated deficit
   
(287,626
)
   
(267,417
)
Total stockholders’ equity
   
2,990
     
12,357
 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
 
$
9,770
   
$
24,673
 

See notes to the consolidated financial statements.

 

NUWELLIS, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except weighted average shares outstanding and per share amounts)

   
Three months ended
December 31,
   
Twelve months ended
December 31,
 
   
2023
   
2022
   
2023
   
2022
 
   
(unaudited)
   
(unaudited)
   
(unaudited)d)
       
                         
Net sales
 
$
2,551
   
$
2,339
   
$
8,864
   
$
8,543
 
     Cost of goods sold
   
1,163
     
1,008
     
3,881
     
3,788
 
        Gross profit
   
1,388
     
1,331
     
4,983
     
4,755
 
Operating expenses:
                               
     Selling, general and administrative
   
3,609
     
4,664
     
17,191
     
17,584
 
     Research and development
   
1,372
     
1,201
     
5,422
     
4,342
 
        Total operating expenses
   
4,981
     
5,865
     
22,613
     
21,926
 
         Loss from operations
   
(3,593
)
   
(4,534
)
   
(17,630
)
   
(17,171
)
     Other income (expense), net
                               
Other income
   
56
     
61
     
154
     
75
 
Financing expense
   
(3,483
)
   
(9,247
)
   
(3,483
)
   
(9,247
)
Change in fair value of warrant liability
   
1,513
     
11,827
     
758
     
11,827
 
         Loss before income taxes
   
(5,507
)
   
(1,893
)
   
(20,201
)
   
(14,516
)
     Income tax expense
   
(2
)
   
(3
)
   
(8
)
   
(9
)
         Net loss
   
(5,509
)
   
(1,896
)
   
(20,209
)
   
(14,525
)
Deemed dividend attributable to Series J Convertible Preferred Stock
   
(2,297
)
   
     
(2,297
)
   
 
Dividend on Series J Convertible Preferred Stock
   
(121
)
   
     
(121
)
   
 
Net loss attributable to common stockholders
 
$
(7,927
)
 
$
(1,896
)
 
$
(22,627
)
 
$
(14,525
)
                                 
Basic and diluted loss per share
 
$
(2.24
)
 
$
(5.00
)
 
$
(11.52
)
 
$
(83.55
)
                                 
Weighted average shares outstanding – basic and diluted
   
3,539,185
     
379,254
     
1,964,406
     
173,846
 
                                 
Other comprehensive loss:
                               
Net loss
 
$
(5,509
)
 
$
(1,896
)
 
$
(20,209
)
 
$
(14,525
)
Unrealized gain (loss) on marketable securities
   
     
6
     
     
80
 
    Foreign currency translation adjustments
   
(6
)
   
(7
)
   
(13
)
   
(7
)
Total comprehensive loss
 
$
(5,515
)
 
$
(1,897
)
 
$
(22,222
)
 
$
(14,452
)

See notes to the consolidated financial statements.



NUWELLIS, INC. AND SUBSIDIARY
Consolidated Statements of Cash Flows
(in thousands)

   
For the years ended December 31,
 
   
2023
   
2022
 
Operating Activities
 
(unaudited)
       
Net loss          
 
$
(20,209
)
  (14,525
)
Adjustments to reconcile net loss to cash flows from operating activities:
             
Depreciation and amortization          
   
362
     
372
 
Stock-based compensation expense          
   
670
     
862
 
Change in fair value of warrant liability
   
(758
)
   
(11,827
)
Financing expense
   
3,483
     
9,247
 
Net realized and unrealized gains on marketable securities
   
(65
)
   
124
 
Changes in operating assets and liabilities:
               
Accounts receivable          
   
(545
)
   
(656
)
Inventory          
   
697
     
140
 
Other current assets          
   
(65
)
   
(68
)
Other assets and liabilities          
   
(7
)
   
(96
)
Accounts payable and accrued expenses          
   
(1,500
)
   
1,278
 
Net cash used in operations          
   
(17,937
)
   
(15,149
)
                 
Investing activities:
               
Additions to intangible assets
   
(99
)
   
 
Proceeds from sales of marketable securities
   
578
     
14,850
 
    Purchase of property and equipment
   
(149
)
   
(122
)
Net cash provided by investing activities          
   
330
     
14,728
 
                 
Financing activities:
               
Proceeds from public stock offerings, net          
   
2,109
     
9,449
 
    Proceeds from Series J Preferred Stock and Warrants
   
1,482
     
 
    Proceeds from the exercise of warrants
   
120
     
 
Payments on finance lease liability          
   
(28
)
   
(26
)
Net cash provided by financing activities          
   
3,683
     
9,423
 
                 
Effect of exchange rate changes on cash          
   
(13
)
   
(7
)
Net increase in cash and cash equivalents          
   
(13,937
)
   
8,995
 
Cash and cash equivalents—beginning of year          
   
17,737
     
8,742
 
Cash and cash equivalents—end of year          
 
$
3,800
      17,737
 
                 
Supplemental schedule of non-cash activities
               
    Inventory transferred to property, plant and equipment
 
$
41
    $ 42
 
Issuance of Common Stock for exercise of Series I Warrants
 
$
7,623
    $  
Issuance of Series J Preferred Stock for exercise of Warrants
 
$
2,927
    $  
Deemed dividend on Series J Preferred Stock
 
$
2,297
    $  
Series J Preferred Stock issued for payment in kind dividend
 
$
121
    $  
                 
Supplemental cash flow information
               
Cash paid for income taxes
 
$
12
    $ 9
 

EX-101.SCH 3 nuwe-20240305.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nuwe-20240305_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 nuwe-20240305_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image0.jpg begin 644 image0.jpg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end GRAPHIC 7 image00001.jpg begin 644 image00001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Mar. 05, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 05, 2024
Entity File Number 001-35312
Entity Registrant Name Nuwellis, Inc.
Entity Central Index Key 0001506492
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 68-0533453
Entity Address, Address Line One 12988 Valley View Road
Entity Address, City or Town Eden Prairie
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55344
City Area Code 952
Local Phone Number 345-4200
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol NUWE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://sunshineheart.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20023378_8k.htm nuwe-20240305.xsd nuwe-20240305_lab.xml nuwe-20240305_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20023378_8k.htm": { "nsprefix": "nuwe", "nsuri": "http://sunshineheart.com/20240305", "dts": { "inline": { "local": [ "ef20023378_8k.htm" ] }, "schema": { "local": [ "nuwe-20240305.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "nuwe-20240305_lab.xml" ] }, "presentationLink": { "local": [ "nuwe-20240305_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://sunshineheart.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240305to20240305", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20023378_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240305to20240305", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20023378_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sunshineheart.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001140361-24-011633-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-011633-xbrl.zip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end XML 18 ef20023378_8k_htm.xml IDEA: XBRL DOCUMENT 0001506492 2024-03-05 2024-03-05 false 0001506492 8-K 2024-03-05 Nuwellis, Inc. DE 001-35312 68-0533453 12988 Valley View Road Eden Prairie MN 55344 952 345-4200 Common Stock, par value $0.0001 per share NUWE NASDAQ false false false false false